Medicare AdvantagePrior AuthMedium impact
Beleodaq® (belinostat) (Revised)
Humana·FL, KY, SC · Oncology, Hematology·Medicaid
Effective date
Nov 26, 2025
We identified it
Jun 25, 2026
Summary
Humana has revised its Beleodaq (belinostat) prior authorization policy effective November 26, 2025, covering Medicare and Medicaid members in Florida, Kentucky, and South Carolina. The policy requires prior authorization for belinostat treatment in relapsed or refractory peripheral T-cell lymphoma (PTCL), with specific exclusion criteria including disease progression on Beleodaq and concomitant use of other HDAC inhibitors. Initial and renewal approvals are valid for 6 months or as determined through clinical review.
Action Required
By November 26, 2025: Billing team must implement prior authorization requirements for Beleodaq (belinostat, HCPCS J9018) in the billing system for all Medicare Advantage, Traditional Medicare, and Medicaid claims (Florida, Kentucky, South Carolina only). Update claim submission workflows to: (1) require documentation of relapsed or refractory PTCL diagnosis; (2) verify member is not experiencing disease progression on Beleodaq; (3) confirm member is not on concomitant Istodax (romidepsin), Zolinza (vorinostat), or Folotyn (pralatrexate); (4) establish 6-month approval intervals with renewal tracking. Providers must submit prior authorization requests before dispensing. Update encounter templates and provider communication materials. Claims submitted without prior authorization will be denied.